					U.S. Patent and Trader	nark Office; U	S. DEPARTMENT OF COMMERC	
Substitu	ite for	form 1449A/PTO		Applicati	on Number	TBA 10 580 944 S November 19, 2004 Mimi ADACHI, et al.		
-	- -	DATA TOTON DYCCE OCT	me	Internati	onal Filing Date			
		RMATION DISCLOSU		First Nam	ned Inventor			
51.		EMENT BY APPLICA	INI	Art Unit		TBA		
		(use as many sheets as necessary)		Examine	r Name	Unassigned		
Sheet		1 of 4		Attorney	Docket Number	64517.000003		
		11.9	S. PAT	ENT DO	CUMENTS			
_	1	0	J. 1 211	MILI DO	COMILITIES		Pages, Columns, Lines, Where	
*Exactine Seitlals	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)		tion Date D-YYYY	Name of Patent Applicant of Cited		Relevant Passages or Relevant Figures Appear	
	1.	US- 2005/0208659 A1	09-22	2-2005	Ikeda, et a	վ.		
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
	<u></u>	US-						
	L	US-						
		US-						
		US-						
		US-						
	L	US-						
	L	US-						
		US-						
l	1	116-						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

EXAMINER SIGNATURE

Substitute for form 1449/PTO					Application Number		ТВА				
						International Filing Date		November 19, 2004			
INFORMATION DISCLOSURE						First Named Inventor		Mimi ADACHI, et al.			
$oldsymbol{STATEMENT}$ BY APPLICANT $oldsymbol{H}$						Art Unit		TBA			
(use as many sheets as necessary)							aminer Name	Unassigned			
Sheet		2 6					torney Docket Number	Unassigned 64517.000003			
Sneet		2 of	4			Ц.		14517.000003			
		- 1			OREIGN I	PAT	ENT DOCUMENTS	· · · · · · · · · · · · · · · · · · ·			
			FOREIGN PATENT DOCUMENT				Date Name of Palentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
*Euminer	Cite	- 1			Publication Dat				TRANSLATION		
folial	No.	Country Code Number-Kind Code (if known)		MM-DD-YY		Applicant of Cited Document	YES		NO		
	2.		wo	02/095026	11-28-200)2	Ikeda, et al.				
							The state of the s				
	<u> </u>										
					•						
										ㅁ	
	·	_									
	<u> </u>	_							무	<u>-</u>	
	-	_								무	
	-								<u>-</u>	믐	
	⊢	-							H	믐	
	┢	\dashv							H	H	
	-								H	믐	
	-	-				_			H	片	
-	-			-					H	H	
									1	吉	
EXAMINER SIGNATURE					1,	DATE CONSIDERED	I				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08B (08/03) (modified)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	te for	form 1449/PTO	Application Number	TBA					
		DATE TO LOCAL DESCRIPTION OF THE PARTY OF TH	International Filing Date	November 19, 2004					
		RMATION DISCLOSURE	First Named Inventor	Mimi ADACHI, et al.					
STA		EMENT BY APPLICANT	Art Unit	TBA					
(use as many sheets as necessary)			Examiner Name	Unassigned					
Sheet		3 of 4	Attorney Docket Number	64517.000003					
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS									
*Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue				LATION			
frétails	No.	number(s), publish	number(s), publisher, city and/or country where published			NO I			
	3.	Proliferative Capacity Induced by Cyclin	Tamamori-Adachi, et al., "Loss of skp2 Dependent Degradation of p27 Limits Cardiomyocyte Proliferative Capacity Induced by Cyclin DINLS/CDK4," 26 th Annual Meeting of the Molecular Biology Society of Japan Program Abstract, November 25, 2003, pg.438, 013-6.						
	4.		Tamamori-Adachi, et al., "Critical Role of Cyclin D1 Nuclear Import in Cardiomyocyte Proliferation," Circulation Research, Vol. 92, No. 1, pg. 1-8, 2003.						
	5.	Poolman, et al., "Altered Expression of Myocyte Hyperplasia in p27 ^{KIPt} Knockout 1999.	Poolman, et al., "Altered Expression of Cell Cycle Proteins and Prolonged Duration of Cardiac Myocyte Hyperplasia in p27 ^{KB1} Knockout Mice," Circulation Research, Vol. 85, No. 2, pg. 117-127, 1999.						
	6.	Kim, et al., "Successful Inactivation of Endogenous Oct-314 and c-mos genes in Mouse Preimplantation Embryos and Oocytes using Short Interfering RNAs," Biochemical and Biophysical Research Communications, Vol. 296, pg. 1372-1377, 2005.							
	7.		Toyoshima, et al., "p27, a Novel Inhibitor of GI Cyclin-Cdk Protein Kinase Activity, Is Related to p21," Cell, Vol. 78, No.1, pg. 67-74, July 15, 1994.						
	8.		Tsvetkov, et al., "p21 ^{Kp1} Ubiquitination and Degradation is Regulated by the SCP ^{Sin2} Complex Through Phosphorylated Thr187 in p27," Current Biology, Vol. 9, No.12, pg. 661-664, 1999.						
	9.	Pasumarthi, et al., "Cardiomyocyte Cell C 1054, 2002.	Pasumarthi, et al., "Cardiomyocyte Cell Cycle Regulation," Circulation Research, Vol. 90, pg. 1044-1054, 2002.						
	 Kirshenbaum, et al., "Adenovirus EIA Represses Cardiac Gene Transcription and Reactivates DNA Synthesis in Ventricular Myocytes, Via Alternative Pocket Protein- and p300-binding Domains," The Journal of Biological Chemistry, Vol. 270, No. 14, pg. 7791-7794, 1995. 								
	11.		Kirshenbaum, et al., "Human B2F-1 Reactivates Cell Cycle Progression in Ventricular Myocytes and Represses Cardiac Gene Transcription," Developmental Biology, Vol. 179, pg. 402-411, 1996.						
	12.	Soonpaa, et al., "Cyclin DI Overexpression Promotes Cardiomyocyte DNA Synthesis and Multinucleation in Transgenic Mice," J. Clin. Invest., Vol. 99, No. 11, pg. 2644-2654, June 1997.							
	 Toyoda, et al., "jumonji Downregulates Cardiac Cell Proliferation by Repressing cyclin D Expression," Developmental Cell, Vol. 5, pg. 85-97, July 2003. 								
EXAM	EXAMINER SIGNATURE DATE CONSIDERED								
		R: Initial if reference considered, whether or not once and not considered. Include copy of this form			citation	if not			

PTO/SB/08B (08/03) (modified)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	te for	form 1449/PTO	Application Number	TBA				
TAIL	'nΤ	RMATION DISCLOSURE	International Filing Date	November 19, 2004				
		EMENT BY APPLICANT	First Named Inventor	Mimi ADACHI, et al.				
318			Art Unit	ТВА				
	,	use as many sheets as necessary)	Examiner Name	Unassigned				
Sheet		4 of 4	Attorney Docket Number	64517.000003				
	_	OTHER DOCUMENTS - NON-	PATENT LITERATURE	DOCUMENTS				
Caming		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the						
Irigals	Cht No.	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				NO		
	14.	Flink, et al., "Changes in E2F Complexes Containing Retinoblastoma Protein Family Members and Increased Cyclin-dependent Kinase Inhibitor Activities During Terminal Differentiation of Cardiomyocytes," J. Mol. Cell. Cardiol., Vol. 30, ps. 563-578, 1998.						
	15.	von Harsdorf, et al. "E2F-1 Overexpression in Cardiomyocytes Induces Downregulation of p21 ^{CPI} and p27 ^{KIPI} and Release of Active Cyclin-Dependent Kinases in the Presence of Insulin-Like Growth Factor I," Circulation Research, Vol. 85, pg. 128-136, 1999.						
	16.	Carrano, et al., "SKP2 is Required for Ubiquitin-mediated Degradation of the CDK Inhibitor p27," Nature Cell Biology, Vol. 1, pg. 193-199, August 1999.						
	18.	Bornstein, et al., "Role of the SCF ^{Stg2} Ubiquitin Ligase in the Degradation of p21 ^{Cpt} in S Phase," The Journal of Biological Chemistry, Vol. 278, No. 28, pg. 25752-25757, July 11, 2003.						
	18.	 Kamura, et al., "Degradation of p57^{Kip2} Mediated By SCP^{Sip2}-dependent Ubiquitylation," Proc. Natl. Acad. Sci. USA, Vol. 100, No. 18, pg. 10231-10236, September 2, 2003. 						
EXAMINER SIGNATURE DATE CONSIDERED								
		R: Initial if reference considered, whether or not one and not considered. Include copy of this form			citation	if not		